Salus Biomed obtained Category III medical device registration from China’s NMPA for its Saluseq Nimbo sequencer, clearing the platform for clinical applications nationwide. The Saluseq Nimbo uses reversible terminator chemistry and delivers single‑end 50 runs in about 2.2 hours and paired‑end150 runs in 7.2 hours, with a reported Q30 >90%. Salus already holds CE‑IVD certification and earlier NMPA approval for another sequencer; the company sees applications across pathogen detection, cancer genomics, reproductive health and genetic screening as it scales clinical installations in China.